Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03673059 · ClinicalTrials.gov registry record · NA
Clinical Trial to Assess the Effects of Topical Lotions on Changes in the Skin Microbiome and Associations With Itch
A NA study of Microbiota, sponsored by Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies.
- Completed
- Registry status
- NA
- Development phase
- 91
- Enrollment target
- 2
- Study locations
NCT03673059: Completed NA study of Microbiota, sponsored by Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies.
NCT03673059 is a NA study of Microbiota that has completed, run by Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies. The registered enrollment target is 91 participants, below the 130-participant average among 10 other Microbiota trials with a reported enrollment target (30% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03673059, a NA study of Microbiota, has completed, sponsored by Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies.
- COMPLETED
- Registry status
- NA
- Development phase
- 91 participants
- Enrollment target
- 2
- Study locations
Study Summary
This was a multi-center, 14-day clinical use study with a 7-day regression period, being conducted to assess the changes in the skin microbiome with two moisturizers in female and male subjects 16-50 years of age with mild to moderate eczema that experienced a recent itch flare up.
Primary Outcome
Changes in the composition (abundance and diversity) of the microbiome communities present on the lesional skin from Baseline to Day 14. The microbiome of the skin of interest was sampled using a sterile swab, sequenced to amplify genomic regions, and analyzed using standard protocols to determine associated organisms, both known and novel, between the two time points.
Conditions Studied
Interventions
- DRUG OTC Eczema Moisturizer Regimen
- OTHER Cosmetic Moisturizer Regimen
Study Locations (2)
Colorado
- Thomas J. Stephens & Associates, Inc. - Colorado Springs
Texas
- Thomas J. Stephens and Associates, Inc. - Richardson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2015-03-27 |
| Est. Completion | 2016-06-13 |
| Phase | NA |
Sponsor
Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies4 total trials
What the finished NCT03673059 record still lists
NCT03673059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 130-participant average among 10 other Microbiota trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Microbiota appearing as the primary indexed condition, and to 2 interventions - of which OTC Eczema Moisturizer Regimen is the first listed.
NCT03673059 reports a single indexed study location in Colorado, Texas.
Frequently Asked Questions
What is clinical trial NCT03673059 about?
NCT03673059 is a clinical study titled "Clinical Trial to Assess the Effects of Topical Lotions on Changes in the Skin Microbiome and Associations With Itch". This was a multi-center, 14-day clinical use study with a 7-day regression period, being conducted to assess the changes in the skin microbiome with two moisturizers in female and male subjects 16-50 years of age with mild to moderate eczema that experienced a recent itch flare up.
What is the current status of trial NCT03673059?
This trial is currently completed. It is a NA study. The enrollment target is 91 participants. The study started on 2015-03-27. Estimated completion is 2016-06-13.
What conditions does trial NCT03673059 study?
This clinical trial studies the following conditions: Microbiota.
What interventions are being tested in trial NCT03673059?
The interventions under investigation include: OTC Eczema Moisturizer Regimen (DRUG), Cosmetic Moisturizer Regimen (OTHER).
Who is sponsoring clinical trial NCT03673059?
This trial is sponsored by Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03673059 being conducted?
This trial has 2 study locations across Colorado, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Microbiota
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03673059's enrollment target sits among peer trials
91 5th of 10 higher than 6 of 10 other Microbiota trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Microbiota trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Flourish: Exploring the Early Infant Gut Microbiome
RECRUITING · NA
-
Capillary Endoscopy Aspiration Catheter
RECRUITING · NA
-
Infant Restore: Efficacy of Microbiome Analysis and Education
ACTIVE NOT RECRUITING · NA
-
DASH INtervention to INvestigate the Gut
ACTIVE NOT RECRUITING · NA
-
Prebiotic Effects of Isomalto-oligosaccharide
COMPLETED · NA
-
Healthy Patients & Effect of Antibiotics
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI